Abstention from filtered coffee reduces the concentrations of plasma homocysteine and serum cholesterol--a randomized

B Christensen1, A Mosdol, L Retterstol

  • 1Department of Medical Genetics, Ullevål University Hospital, Oslo, Norway. christensen@ioks.uio.no

Insights

Quitting filtered coffee consumption, even in moderate amounts, can lower plasma total homocysteine (tHcy) and serum total cholesterol levels. This reduction is significant for individuals at risk of ischemic heart disease (IHD).

Area of Science:

  • Cardiovascular Health
  • Nutritional Science
  • Biochemistry

Background:

  • Elevated plasma total homocysteine (tHcy) and serum total cholesterol are established risk factors for ischemic heart disease (IHD).
  • Previous research indicated that high intake of unfiltered coffee may increase tHcy and total cholesterol levels.

Purpose of the Study:

  • To investigate the impact of coffee consumption, using common doses and brewing methods in southeastern Norway, on tHcy and total cholesterol concentrations.
  • To assess the effects of abstaining from coffee versus moderate and high consumption.

Main Methods:

  • A 6-week, unblinded, controlled intervention trial involving 191 healthy, non-smoking coffee drinkers.
  • Participants were randomized into three groups: no coffee, 1-3 cups/day, or >=4 cups/day, consuming coffee as usual.
  • Blood samples were collected at baseline, 3 weeks, and 6 weeks; dietary data were gathered via questionnaire.

Main Results:

  • Abstaining from coffee for 6 weeks led to a significant decrease in tHcy (1.08 micromol/L) and total cholesterol (0.28 mmol/L) in regular filtered coffee drinkers.
  • These results remained consistent after adjusting for potential confounding factors.
  • The majority (97%) of participants regularly consumed caffeinated filtered coffee.

Conclusions:

  • Abstaining from commonly consumed filtered coffee is associated with reduced levels of tHcy and total cholesterol.
  • This finding suggests a potential dietary intervention strategy for managing cardiovascular risk factors.
Abstract

Related Concept Videos

Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...